查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1576840

青光眼市场：按类型、诊断方法、治疗、最终用户、年龄组划分 - 全球预测 2025-2030

Glaucoma Market by Type (Angle-Closure Glaucoma, Normal-Tension Glaucoma, Primary Open-Angle Glaucoma), Diagnosis Method (Gonioscopy, Tonometry, Visual Field Test), Treatment, End-User, Age Group - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年青光眼市场价值为72.3亿美元，预计到2024年将达到76亿美元，复合年增长率为5.56%，预计到2030年将达到105.6亿美元。

KEYWORD 是全球不可逆转失明的主要原因，由于人口老化加剧和盛行率不断上升，需要进行广泛的市场研究。该市场包括用于管理和治疗青光眼的各种诊断设备、手术设备、药物和治疗解决方案。预防视力丧失、显着改善患者生活品质的需求强调了对先进青光眼治疗的需求。应用范围涵盖临床环境、研究机构和医疗机构，利用外科手术的进步、创新的药物传递系统和增强的诊断工具来更好地管理眼内压和视网膜健康。最终用途范围广泛，包括医院、眼科诊所、居家医疗场所以及日益增长的个人化医疗趋势。市场成长受到手术和诊断设备技术进步、意识提升以及政府支持研究和预防措施的倡议等因素的显着影响。新的机会在于微创手术技术、基于人工智慧和物联网的诊断工具以及个人化治疗方法的发展。然而，市场成长面临治疗成本高、低收入地区缺乏公平准入以及监管障碍等限制。此外，青光眼复杂的病理生理学及其无症状性对早期诊断和治疗依从性提出了挑战。基因治疗、神经保护、缓释性药物传输系统和基于远端医疗的患者管理等领域的创新可以提供竞争优势。市场的本质是动态的，促进生物技术公司、医疗保健提供者和学术机构之间的合作。鼓励公司专注于合作研究，投资新的数位健康解决方案，并扩展到开拓的市场，以抓住潜在的成长并改善全球营运。

主要市场统计
基准年[2023] 72.3亿美元
预测年份 [2024] 76亿美元
预测年份 [2030] 105.6亿美元
复合年增长率（%） 5.56%

市场动态：揭示快速发展的青光眼市场的关键市场洞察

供需的动态交互作用正在改变青光眼市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 微创手术的采用增加有助于市场扩张（青光眼）
    • 联合治疗在青光眼治疗中的广泛应用推动了市场开拓
    • 由于青光眼管理远端医疗和远端监控服务的扩展，市场扩大
    • 透过开发青光眼新型药物传输系统来提高患者的依从性和治疗结果
  • 市场限制因素
    • 介绍新的青光眼治疗方法 影响监管挑战和核准过程中的延误
    • 由于缺乏对青光眼的认识和教育而延误诊断和治疗
  • 市场机会
    • 透过先进的基因疗法和个人化医疗方法改变青光眼治疗
    • 利用人工智慧和机器学习加强青光眼的早期检测和管理
    • 开发创新的微创手术技术以改善青光眼患者的预后和康復
  • 市场挑战
    • 缺乏关于及早发现青光眼症状的公众意识和教育
    • 农村和欠发达地区青光眼专业护理的可用性和可近性有限

波特五力：驾驭青光眼市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解青光眼市场的外部影响

外部宏观环境因素在塑造青光眼市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解青光眼市场的竞争格局

对青光眼市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵青光眼市场供应商的绩效评估

FPNV定位矩阵是评估青光眼市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製青光眼市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，青光眼市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 微创手术的增加有助于市场扩张
      • 在治疗中增加联合治疗的使用推动了市场的开拓
      • 透过扩大远端医疗和远端监控服务来扩大市场范围
      • 开发新的药物输送系统以提高患者的依从性和结果
    • 抑制因素
      • 监管挑战和缓慢的核准流程影响新青光眼治疗方法的推出
      • 缺乏对青光眼的认识和教育导致诊断和治疗的延误
    • 机会
      • 透过先进的基因疗法和个人化医疗方法实现青光眼治疗的创新
      • 利用人工智慧和机器学习增强青光眼的早期检测和管理
      • 开发创新的微创手术技术以改善患者的治疗效果和康復
    • 任务
      • 大众缺乏对青光眼症状早期发现的认识与教育
      • 农村和发展中地区的专科护理较少且难以获得
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章青光眼市场：依类型

  • 闭角型青光眼
  • 正常眼压性青光眼
  • 原发性开角型青光眼

第七章 青光眼市场：依诊断方法

  • 房角镜检查
  • 眼压测量
  • 视野测试

第八章青光眼市场：依治疗分类

  • 雷射治疗
    • 氩气雷射小梁网整型术
    • 选择性雷射小梁网整型术
  • 药物治疗
    • α促效剂
    • β受体阻断剂
    • 碳酸酐酶抑制剂
    • 前列腺素琴酒
  • 外科手术
    • 引流植入植入
    • 微创青光眼手术
    • 切除术

第 9 章 青光眼市场：依最终使用者分类

  • 门诊手术中心
  • 医院
  • 眼科诊所
  • 研究所

第10章青光眼市场：依年龄组

  • 成人用
  • 老年病
  • 小儿科

第十一章美洲青光眼市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太青光眼市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲青光眼市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • 1. Aerie Pharmaceuticals
  • 2. Alcon
  • 3. Allergan
  • 4. Allergan (acquired by Abbvie)
  • 5. Bausch Health
  • 6. EyeGate Pharmaceuticals
  • 7. Eyenovia
  • 8. Glaukos Corporation
  • 9. Inotek Pharmaceuticals
  • 10. Johnson & Johnson
  • 11. Merck
  • 12. Nicox
  • 13. Novartis
  • 14. Pfizer
  • 15. Regeneron Pharmaceuticals
  • 16. Roche
  • 17. Sanofi
  • 18. Santen Pharmaceutical
  • 19. Teva Pharmaceutical
  • 20. Valeant Pharmaceuticals International
Product Code: MRR-1A1A064C034E

The Glaucoma Market was valued at USD 7.23 billion in 2023, expected to reach USD 7.60 billion in 2024, and is projected to grow at a CAGR of 5.56%, to USD 10.56 billion by 2030.

Glaucoma, a leading cause of irreversible blindness globally, demands extensive market research due to the growing aging population and increasing prevalence of the disease. The scope of this market includes a diverse array of diagnostic equipment, surgical devices, pharmaceuticals, and therapeutic solutions aimed at managing and treating glaucoma. The necessity for advanced glaucoma treatments is underscored by the need to prevent vision loss, thus ensuring a substantial quality of life for patients. Applications span clinical settings, research institutions, and healthcare facilities, utilizing surgical advancements, innovative drug delivery systems, and enhanced diagnostic tools to better manage intraocular pressure and retinal health. The end-use scope is broad, encompassing hospitals, specialized ophthalmology clinics, and home care settings, with an increasing trend toward personalized medicine. Market growth is significantly influenced by factors such as technological advancements in surgical and diagnostic devices, higher awareness among patients due to robust community outreach, and government initiatives to boost research and preventive measures. Emerging opportunities lie in developing minimally invasive surgical techniques, AI and IoT-based diagnostic tools, and personalized therapeutic approaches. However, market growth faces limitations such as high costs of treatment, lack of equitable access in low-income regions, and regulatory hurdles. Moreover, complex pathophysiology of glaucoma and its asymptomatic nature pose challenges in early diagnosis and treatment adherence. Innovating in areas like gene therapy, neuroprotection, sustained-release drug delivery systems, and telemedicine-based patient management could provide a competitive edge. The market's nature is dynamic, fostering collaboration between biotech firms, healthcare providers, and academic institutions. Businesses are recommended to focus on collaborative research, investing in emerging digital health solutions, and expanding into untapped markets to seize latent growth potential and improve glaucoma management on a global scale.

KEY MARKET STATISTICS
Base Year [2023] USD 7.23 billion
Estimated Year [2024] USD 7.60 billion
Forecast Year [2030] USD 10.56 billion
CAGR (%) 5.56%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Glaucoma Market

The Glaucoma Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising adoption of minimally invasive glaucoma surgeries contributing to market expansion
    • Increasing utilization of combination therapies in glaucoma treatment fostering market development
    • Expansion of telemedicine and remote monitoring services for glaucoma management enhancing market reach
    • Development of novel drug delivery systems for glaucoma improving patient compliance and outcomes
  • Market Restraints
    • Regulatory challenges and slow approval process affecting the introduction of new glaucoma therapies
    • Lack of awareness and education about glaucoma leading to delayed diagnosis and treatment
  • Market Opportunities
    • Revolutionizing glaucoma treatment through advanced gene therapy and personalized medicine approaches
    • Leveraging artificial intelligence and machine learning to enhance early glaucoma detection and management
    • Developing innovative and less-invasive surgical techniques for glaucoma patients to improve outcomes and recovery
  • Market Challenges
    • Lack of awareness and education on early detection of glaucoma symptoms among the general population
    • Limited availability and accessibility of specialized glaucoma care in rural and underdeveloped regions

Porter's Five Forces: A Strategic Tool for Navigating the Glaucoma Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Glaucoma Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Glaucoma Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Glaucoma Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Glaucoma Market

A detailed market share analysis in the Glaucoma Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Glaucoma Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Glaucoma Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Glaucoma Market

A strategic analysis of the Glaucoma Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Glaucoma Market, highlighting leading vendors and their innovative profiles. These include Aerie Pharmaceuticals, Alcon, Allergan, Allergan (acquired by Abbvie), Bausch Health, EyeGate Pharmaceuticals, Eyenovia, Glaukos Corporation, Inotek Pharmaceuticals, Johnson & Johnson, Merck, Nicox, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi, Santen Pharmaceutical, Teva Pharmaceutical, and Valeant Pharmaceuticals International.

Market Segmentation & Coverage

This research report categorizes the Glaucoma Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Angle-Closure Glaucoma, Normal-Tension Glaucoma, and Primary Open-Angle Glaucoma.
  • Based on Diagnosis Method, market is studied across Gonioscopy, Tonometry, and Visual Field Test.
  • Based on Treatment, market is studied across Laser Treatment, Medication, and Surgery. The Laser Treatment is further studied across Argon Laser Trabeculoplasty and Selective Laser Trabeculoplasty. The Medication is further studied across Alpha Agonists, Beta Blockers, Carbonic Anhydrase Inhibitors, and Prostaglandin Analogs. The Surgery is further studied across Drainage Implants, Minimally Invasive Glaucoma Surgery, and Trabeculectomy.
  • Based on End-User, market is studied across Ambulatory Surgery Centers, Hospitals, Ophthalmic Clinics, and Research Institutes.
  • Based on Age Group, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising adoption of minimally invasive glaucoma surgeries contributing to market expansion
      • 5.1.1.2. Increasing utilization of combination therapies in glaucoma treatment fostering market development
      • 5.1.1.3. Expansion of telemedicine and remote monitoring services for glaucoma management enhancing market reach
      • 5.1.1.4. Development of novel drug delivery systems for glaucoma improving patient compliance and outcomes
    • 5.1.2. Restraints
      • 5.1.2.1. Regulatory challenges and slow approval process affecting the introduction of new glaucoma therapies
      • 5.1.2.2. Lack of awareness and education about glaucoma leading to delayed diagnosis and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Revolutionizing glaucoma treatment through advanced gene therapy and personalized medicine approaches
      • 5.1.3.2. Leveraging artificial intelligence and machine learning to enhance early glaucoma detection and management
      • 5.1.3.3. Developing innovative and less-invasive surgical techniques for glaucoma patients to improve outcomes and recovery
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness and education on early detection of glaucoma symptoms among the general population
      • 5.1.4.2. Limited availability and accessibility of specialized glaucoma care in rural and underdeveloped regions
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Glaucoma Market, by Type

  • 6.1. Introduction
  • 6.2. Angle-Closure Glaucoma
  • 6.3. Normal-Tension Glaucoma
  • 6.4. Primary Open-Angle Glaucoma

7. Glaucoma Market, by Diagnosis Method

  • 7.1. Introduction
  • 7.2. Gonioscopy
  • 7.3. Tonometry
  • 7.4. Visual Field Test

8. Glaucoma Market, by Treatment

  • 8.1. Introduction
  • 8.2. Laser Treatment
    • 8.2.1. Argon Laser Trabeculoplasty
    • 8.2.2. Selective Laser Trabeculoplasty
  • 8.3. Medication
    • 8.3.1. Alpha Agonists
    • 8.3.2. Beta Blockers
    • 8.3.3. Carbonic Anhydrase Inhibitors
    • 8.3.4. Prostaglandin Analogs
  • 8.4. Surgery
    • 8.4.1. Drainage Implants
    • 8.4.2. Minimally Invasive Glaucoma Surgery
    • 8.4.3. Trabeculectomy

9. Glaucoma Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgery Centers
  • 9.3. Hospitals
  • 9.4. Ophthalmic Clinics
  • 9.5. Research Institutes

10. Glaucoma Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adult
  • 10.3. Geriatric
  • 10.4. Pediatric

11. Americas Glaucoma Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Glaucoma Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Glaucoma Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aerie Pharmaceuticals
  • 2. Alcon
  • 3. Allergan
  • 4. Allergan (acquired by Abbvie)
  • 5. Bausch Health
  • 6. EyeGate Pharmaceuticals
  • 7. Eyenovia
  • 8. Glaukos Corporation
  • 9. Inotek Pharmaceuticals
  • 10. Johnson & Johnson
  • 11. Merck
  • 12. Nicox
  • 13. Novartis
  • 14. Pfizer
  • 15. Regeneron Pharmaceuticals
  • 16. Roche
  • 17. Sanofi
  • 18. Santen Pharmaceutical
  • 19. Teva Pharmaceutical
  • 20. Valeant Pharmaceuticals International

LIST OF FIGURES

  • FIGURE 1. GLAUCOMA MARKET RESEARCH PROCESS
  • FIGURE 2. GLAUCOMA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GLAUCOMA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GLAUCOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GLAUCOMA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GLAUCOMA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GLAUCOMA MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GLAUCOMA MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GLAUCOMA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GLAUCOMA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GLAUCOMA MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GLAUCOMA MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES GLAUCOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES GLAUCOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. GLAUCOMA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. GLAUCOMA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GLAUCOMA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GLAUCOMA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GLAUCOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GLAUCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLAUCOMA MARKET DYNAMICS
  • TABLE 7. GLOBAL GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GLAUCOMA MARKET SIZE, BY ANGLE-CLOSURE GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GLAUCOMA MARKET SIZE, BY NORMAL-TENSION GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GLAUCOMA MARKET SIZE, BY PRIMARY OPEN-ANGLE GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GLAUCOMA MARKET SIZE, BY GONIOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GLAUCOMA MARKET SIZE, BY TONOMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GLAUCOMA MARKET SIZE, BY VISUAL FIELD TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GLAUCOMA MARKET SIZE, BY LASER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GLAUCOMA MARKET SIZE, BY ARGON LASER TRABECULOPLASTY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GLAUCOMA MARKET SIZE, BY SELECTIVE LASER TRABECULOPLASTY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GLAUCOMA MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GLAUCOMA MARKET SIZE, BY ALPHA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GLAUCOMA MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GLAUCOMA MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GLAUCOMA MARKET SIZE, BY PROSTAGLANDIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GLAUCOMA MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GLAUCOMA MARKET SIZE, BY DRAINAGE IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GLAUCOMA MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GLAUCOMA MARKET SIZE, BY TRABECULECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GLAUCOMA MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GLAUCOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GLAUCOMA MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GLAUCOMA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL GLAUCOMA MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL GLAUCOMA MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL GLAUCOMA MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS GLAUCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES GLAUCOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 332. SWEDEN GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 333. SWEDEN GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 338. SWEDEN GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 340. SWITZERLAND GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 342. SWITZERLAND GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 344. SWITZERLAND GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 346. SWITZERLAND GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 348. TURKEY GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 349. TURKEY GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 350. TURKEY GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 351. TURKEY GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 352. TURKEY GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 353. TURKEY GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 354. TURKEY GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 355. TURKEY GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 356. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 357. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 358. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 364. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 365. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 366. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 367. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 368. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 369. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 370. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 371. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 372. GLAUCOMA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 373. GLAUCOMA MARKET, FPNV POSITIONING MATRIX, 2023